BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 32448308)

  • 1. Symphony of epigenetic and metabolic regulation-interaction between the histone methyltransferase EZH2 and metabolism of tumor.
    Zhang T; Gong Y; Meng H; Li C; Xue L
    Clin Epigenetics; 2020 May; 12(1):72. PubMed ID: 32448308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.
    Au SL; Wong CC; Lee JM; Wong CM; Ng IO
    PLoS One; 2013; 8(6):e68226. PubMed ID: 23826380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EZH2-Targeted Therapies in Cancer: Hype or a Reality.
    Eich ML; Athar M; Ferguson JE; Varambally S
    Cancer Res; 2020 Dec; 80(24):5449-5458. PubMed ID: 32978169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis.
    Zeng Y; Qiu R; Yang Y; Gao T; Zheng Y; Huang W; Gao J; Zhang K; Liu R; Wang S; Hou Y; Yu W; Leng S; Feng D; Liu W; Zhang X; Wang Y
    Cell Rep; 2019 Nov; 29(6):1482-1498.e4. PubMed ID: 31693890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic regulation of enhancer of zeste homolog 2 (EZH2) -Yin Yang 1 (YY1) axis in cancer.
    Chandnani N; Gupta I; Thakkar V; Sarkar K
    Pathol Res Pract; 2023 Nov; 251():154885. PubMed ID: 37862922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EZH2, a prominent orchestrator of genetic and epigenetic regulation of solid tumor microenvironment and immunotherapy.
    Sun S; Yu F; Xu D; Zheng H; Li M
    Biochim Biophys Acta Rev Cancer; 2022 Mar; 1877(2):188700. PubMed ID: 35217116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.
    Song H; Yu Z; Sun X; Feng J; Yu Q; Khan H; Zhu X; Huang L; Li M; Mok MTS; Cheng ASL; Gao Y; Feng H
    EBioMedicine; 2018 Sep; 35():155-166. PubMed ID: 30150059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EZH2, an on-off valve in signal network of tumor cells.
    Sun S; Yu F; Zhang L; Zhou X
    Cell Signal; 2016 May; 28(5):481-487. PubMed ID: 26876615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.
    Christofides A; Karantanos T; Bardhan K; Boussiotis VA
    Oncotarget; 2016 Dec; 7(51):85624-85640. PubMed ID: 27793053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?
    Yan KS; Lin CY; Liao TW; Peng CM; Lee SC; Liu YJ; Chan WP; Chou RH
    Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28561778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EZH2 as a potential target in cancer therapy.
    McCabe MT; Creasy CL
    Epigenomics; 2014 Jun; 6(3):341-51. PubMed ID: 25111487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrative Multi-Omics Analysis of Oncogenic EZH2 Mutants: From Epigenetic Reprogramming to Molecular Signatures.
    Aldana J; Gardner ML; Freitas MA
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural assembly of Polycomb group protein and Insight of EZH2 in cancer progression: A review.
    Gautam N; Kaur M; Kaur S
    J Cancer Res Ther; 2021; 17(2):311-326. PubMed ID: 33063698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging Roles of LncRNAs in the EZH2-regulated Oncogenic Network.
    Hao A; Wang Y; Stovall DB; Wang Y; Sui G
    Int J Biol Sci; 2021; 17(13):3268-3280. PubMed ID: 34512145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EZH2-mediated development of therapeutic resistance in cancer.
    Kaur P; Shankar E; Gupta S
    Cancer Lett; 2024 Apr; 586():216706. PubMed ID: 38331087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator.
    Kim J; Lee Y; Lu X; Song B; Fong KW; Cao Q; Licht JD; Zhao JC; Yu J
    Cell Rep; 2018 Dec; 25(10):2808-2820.e4. PubMed ID: 30517868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EZH2 is involved in silencing of WNT5A during epithelial-mesenchymal transition of colon cancer cell line.
    Tao J; Shi L; Huang L; Shi H; Chen H; Wang Y; Wang T
    J Cancer Res Clin Oncol; 2017 Nov; 143(11):2211-2219. PubMed ID: 28748258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromatin remodeling by the histone methyltransferase EZH2 drives lung pre-malignancy and is a target for cancer prevention.
    Tellez CS; Picchi MA; Juri D; Do K; Desai DH; Amin SG; Hutt JA; Filipczak PT; Belinsky SA
    Clin Epigenetics; 2021 Feb; 13(1):44. PubMed ID: 33632299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EZH2 as an Epigenetic Regulator of Cardiovascular Development and Diseases.
    Yuan JL; Yin CY; Li YZ; Song S; Fang GJ; Wang QS
    J Cardiovasc Pharmacol; 2021 Aug; 78(2):192-201. PubMed ID: 34029268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting histone methyltransferase EZH2 as cancer treatment.
    Kondo Y
    J Biochem; 2014 Nov; 156(5):249-57. PubMed ID: 25179367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.